Preventing the gastrointestinal consequences of stress-related mucosal disease

Current Medical Research and Opinion

Volumn 21, Issue 1, 2005, Pages 11-18

  Metz, David C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Histamine2 receptor antagonists (H2RAs); Proton pump inhibitors; Stress related mucosal disease (SRMD)

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; BICARBONATE; CIMETIDINE; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

CLINICAL TRIAL; CRITICAL ILLNESS; DIGESTIVE SYSTEM ULCER; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; META ANALYSIS; MORTALITY; PNEUMONIA; PROPHYLAXIS; REVIEW; RISK FACTOR; STOMACH ACID SECRETION; STOMACH PH; STRESS; STRESS RELATED MUCOSAL DISEASE; STRESS ULCER; SUSPENSION; SYSTEMATIC REVIEW; UPPER GASTROINTESTINAL BLEEDING;

EID: 14744273872     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X16777     Document Type: Review

References (41)

1. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-33
2. Phillips JO, Metzler MH, Palmieri TL, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800
3. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-9
4. Morris J, Karlstadt R, Blatcher D, Field B, McDevitt M. Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH ≥ 4.0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients. Crit Care Med 2002;29:A147
5. Laine LA, Margolis B, Bagin RG, et al. Double-blind trial of omeprazole-immediate release oral suspension (OME-IR SUSP) vs. intravenous cimetidine (IV CIM) for prevention of upper gastrointestinal (UGI) bleeding in critically ill patients. Gastroenterology 2004;126:A-77
6. Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? Am J Gastroenterol 1995;90:708-12
7. Vorder Bruegge WF, Peura DA. Stress-related mucosal damage: review of drug therapy. J Clin Gastroenterol 1990;12(Suppl 2): S35-S40
8. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients [Canadian Critical Care Trials Group]. New Engl J Med 1994;330:377-81
9. Harris SK, Bone RC, Ruth WE. Gastrointestinal hemorrhage in patients in a respiratory intensive care unit. Chest 1977;72:301-4
10. Schuster DP, Rowley H, Feinstein S, McGue MK, Zuckerman GR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984;76:623-30
11. Lewis JD, Shin EJ, Metz DC. Characterization of gastrointestinal bleeding in severely ill hospitalized patients. Crit Care Med 2000;28:46-50
12. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-75
13. Erstad BL, Camamo JM, Miller MJ, Webber AM, Fortune J. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med 1997;25:1678-84
14. Fiddian-Green RG, McGough E, Pittenger G, Rothman E. Predictive value of intramural pH and other risk factors for massive bleeding from stress ulceration. Gastroenterology 1983;85:613-20
15. Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest 2001;119:1222-41
16. Silen W. The prevention and management of stress ulcers. Hosp Pract 1980;15:93-100
17. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis [ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998]. Am J Health Syst Pharm 1999;56:347-79
18. Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med 1991;91:519-27
19. Martin LF, Booth FV, Karlstadt RG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30
20. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96
21. Wolfe MM, Soll AH. The physiology of gastric acid secretion. New Engl J Med 1988;319:1707-15
22. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994;106:60-4
23. Prevacid [package insert]. Lake Forest, IL: TAP Pharmaceuticals, Inc. 2002
24. Sostek MB, Chen Y, Skammer W, et al. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing. Aliment Pharmacol Ther 2003;18:581-6
25. Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999;56:S18-S21
26. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000;14:887-92
27. Ferron GM, Ku S, Abell M, et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health Syst Pharm 2003;60:1324-9
28. Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically Ill patients. Am J Gastroenterol 1997;92:79-83
29. Anon. Zegerid (omeprazole) prescribing information. San Diego (CA): Santarus, Inc.; 2004
30. Song JC, Quercia RA, Fan C, Tsikouris J, White CM. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm 2001;58:689-94
31. Dive A, Moulart M, Jonard P, Jamart J, Mahieu P. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Crit Care Med 1994;22:441-7
32. Harris CE, Griffiths RD, Freestone N, et al. Intestinal permeability in the critically ill. Intensive Care Med 1992;18:38-41
33. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. J Am Med Assoc 1996;275:308-14
34. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation [Canadian Critical Care Trials Group]. New Engl J Med 1998;338:791-7
35. Morris JA. Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH > 4 compared with continuous infusion H2-receptor antagonist in intensive care unit (ICU) patients [abstract 117]. Crit Care Med 2002;30
36. Smith JS, Karlstadt R, Blatcher B, Field B. Gastric pH improvement from NPO to enteral-fed period with intermittent intravenous (IV) pantoprazole (P) vs. continuously infused cimetidine (C). Presented at the American College of Gastroenterology 67th Annual Scientific Meeting; October 21-23, 2002; Seattle, WA [abstract 143]. Am J Gastroenterol 2002;97:S47
37. Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994;120:653-62
38. Eddleston JM, Vohra A, Scott P, et al. A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients. Crit Care Med 1991;19:1491-6
39. Simms HH, DeMaria E, McDonald L, et al. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma 1991;31:531-6
40. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. New Engl J Med 1987;317:1376-82
41. Ryan P, Dawson J, Teres D, Celoria G, Navab F. Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate. Arch Surg 1993;128:1353-7